Dynacure announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. US 10, 865, 414 related to DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein, for the treatment of Myotubular and Centronuclear Myopathies.
January 26, 2021
· 5 min read